1. Home
  2. Vol 53, No 3 (2021)
  3. Kartika

Wound Healing in Diabetic Foot Ulcer Patients Using Combined Use of Platelet Rich Fibrin and Hyaluronic Acid, Platelet Rich Fibrin and Placebo: An Open Label, Randomized Controlled Trial

Ronald Winardi Kartika, Idrus Alwi, Franciscus D Suyatna, Em Yunir, Sarwono Waspadji, Suzana Immanuel, Saptawati Bardosono, Saleha Sungkar, Jusuf Rachmat, Mirta Hediyati, Todung Silalahi

Abstract


Background: Autologous platelet-rich fibrin (A-PRF) is an adjunctive method for diabetic foot ulcer (DFU) in addition to glycaemic control and debridement. This study aimed to evaluate the role of A-PRF + hyaluronic acid (HA), A-PRF and sodium chloride 0.9% (control) in DFU wound healing. Nowaday, the use of  PRF autologous consider as adjuvant therapy in DFU treatment. Methods: This open-label randomized controlled trial was conducted at Koja District Hospital and Gatot Soebroto Hospital from July 2019 to April 2020. DFU patients with wound duration of three months, Wagner-2, and ulcer size < 40 cm2 were recruited and randomly assigned into A-PRF + AH, A-PRF and control group. On day-0, day-3 and day -7, samples and photographs were taken. Samples were analysed with ELISA and photographs were analysed with ImageJ to calculate granulation index (GI). Statistical analysis was performed using SPSS version 20. Results: Topical therapy with A-PRF + AH was associated with a significant increase in VEGF from day 0 (232.8 pg/mg) vs day 7 (544.5 pg/mg) compared to A-PRF on day 0 (185.7 pg/mg) vs day 7 (272.8 pg/mg), and the controls on day 0 (183.7 pg/mg) vs day 7 (167.4 pg/mg). On evaluation  of VEGF swab, there is increasing significantly in A-PRF+HA group compare others group in day -3 ( p=0.022) and day -7 (p= 0.001).In the A-PRF + AH group, there was a significant decrease in IL-6 from day 0 (106.4 pg/mg) vs day 7 (88.7 pg/mg) compared with PRF on day 0 (91.9 pg/mg) vs day 7 (48,8 pg/mg). IL-6 was increased in the control group from day 0 (125.3 pg/mg) vs day 7 (167.9 pg/mg). On evaluation  of IL-6 swab, there is decreasing significantly in A-PRF+HA group compare others group in day -7 (p= 0.041). Conclusion: The PRF + HA combination increased angiogenesis and reduced inflammation in DFUs and may represent a new DFU therapy.

Keywords


diabetic foot ulcer; platelet-rich fibrin; hyaluronic acid

References


Carvajal Am, Gluud C, Nicola S, Racines DS, Reveiz L, Olivia P. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015;28(10): 548−55.

Amstrong DG, Cohen K, Courric S, Bharara M, Marston W. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol. 2011;5(6): 1591–5.

Jindatanmanusan P, Luanraksa S, Boonsiri T, Nimmanon T, Arnutti P. Wound fluid matrix metalloproteinase-9 as a potential predictive marker for the poor healing outcome in diabetic foot ulcers. Pathol Res Int. 2018;25(4):1−6.

Kany S, Tilman K, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019;20(23): 6008.

Zubair M, Jamal A. Role of growth factors and cytokines in diabetic foot ulcer healing. Rev Endocr Metab Disord. 2019;20(8):1−11.

Tiaka EK, Papanas N, Mmanolakis N, Georgiadis G, Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Perspectives Vascular Surgery. 2012;24(1):37-44.

Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. Platelet-rich therapies for musculoskeletal soft tissue injuries. Cochrane Database Syst Rev. 2014;29: 7−19.

Evert P, Onichi K, Jayaram P, Lana JF, Meutner K. Platelet-rich plasma L new performance understandngs and therapeutic consideration in 2020. Int J Mol Sci. 2020;21(20):7794; https://doi.org/10.3390/ijms21207794.

Caruana A, Savina D, Macedo J, Soares S. From platelet-rich plasma to advanced-platelet-rich Fibrin: Biological achievements and clinical advances in modern surgery. Eur J Dent. 2019;13(2):280–6.

Raeissadat S, Rayegani S, Hassanabadi H. Knee osteoarthritis injection choices: platelet- rich plasma (PRP) versus hyaluronic acid (a one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 2015;8:18.

Ramos-Torrecillas J, García-Martínez O, De Luna-Bertos E, Oca~Na-Peinado Fm, Ruiz C. Effectiveness of platelet-rich plasma and hyaluronic acid for the treatment and care of pressure ulcers. Biol Res Nurs. 2015;17:1528.

Anikumar TV, Muhamed J, Jose A, et al. Advantage of hyaluronic acid as a component of fibrin sheet for care of acute wound. Biologicals. 2011;39(2):81-8. doi 10.1016/j.biologicals.2011.01.003

Sridharan K, Sivaramakrishnan G. Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(3):434–44. DOI: 10.1111/bcp.13470

Drela E, Kulwas A, Wieslaw J, Goralczyk B , Boinska J, Drewniak W. VEGF-A and PDGF-BB angiogenic factors and the stage of diabetic foot syndrome advancement. Endocrinol. 2014;65(4):30612.

Amoli M, Ranjbar S, Roohipour N, Sayahpour F, Amiri P, Zahedi P. VEGF gene polymorphism association with diabetic foot ulcer. Diabetes Res Clin Pract. 2011;93:2159.

Tahergorabi Z, Khazae M. Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med. 2012;3(12):827–38.

Perez AG, Rodrigues AA, Luzo AC, Lana JF. Fibrin network architectures in pure platelet-rich plasma characterized by fiber radius and correlated with clotting time. J Mater Sci Mater Med. 2014;25(8):1967-77. doi: 10.1007/s10856-014-5235-z.

Pardue E, Ibrahim S, Ramamurthi A. Role of hyaluronan in angiogenesis and its utility to angiogenic tissue engineering. Organogenesis. 2008;4(4): 203–14.

Ilio K, FurukawaKI, Tsuda E, et.al. Hyaluronic acid induces the release of growth factors from platelet-rich plasma Asia-Pacific Journal of Sports Medicine. Arthroscopy, Rehabilitation and Technology. 2016;4: 2732.

Garbin LC, Olver CS. Platelet-rich products and their application to osteoarthritis. J Equine Vet Sci. 2020;86(10):10-18. doi: 10.1016/j.jevs.2019.102820.

Transforming Growth Factor-β1 (TGF-β1)-stimulated Fibroblast to Myofibroblast Differentiation Is Mediated by Hyaluronan (HA)-facilitated Epidermal Growth Factor Receptor (EGFR) and CD44 Co-localization in Lipid Rafts. J. Bio Chemistry. 2013;288(21):14824-38. doi10.1074/jbc.M113.451336

Yazdanpanah L, Nasiri M, Adarvishi S, Literature review on the management of diabetic foot ulcer, World J Diabetes. 2015;6(1):37-53.

doi: 10.4239/wjd.v6.i1.37

Chen WH, Lo WC, Hsu WC. Synergistic anabolic actions of hyaluronic acid and platelet-rich plasma on cartilage regeneration in osteoarthritis therapy. Biomaterials. 2014;35:9599−607.

Jayakumar R, Prabaharan M, Kumar S, Tamura H, Biomaterials based on chitin and chitosan in wound dressing applications. Biotech Adv. 2012(29):2322-337.


Full Text: PDF

Refbacks

  • There are currently no refbacks.